Can a simple pill shield transplant patients from deadly fungal infections?
NCT ID NCT04725942
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether the drug posaconazole can prevent fungal lung infections in people who have had a stem cell transplant. 360 patients took the drug for 90 days after their transplant. Researchers checked drug levels in the blood and tracked how many patients got infections. The goal was to find the right dose to keep patients safe.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- posaconazole tablets
- What this could lead to
- If successful, this could confirm that posaconazole is a safe and effective way to prevent serious fungal lung infections in stem cell transplant patients.
- What could go wrong
- This is an observational study, not a randomized trial, so results may be less definitive. The drug may not prevent all infections and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
360 people
The number who actually took part.
- Started
-
Feb 2021
- Finished
-
Jun 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Hematopoietic stem cell transplant patients treated with Posaconazole tablets
- Ages
-
13 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 13 years old * The primary causes of hematopoietic stem cell transplantation include aplastic anemia, acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, or other hematologic diseases in patients pretreated for hematopoietic stem cell transplantation. The types of transplantation include autologous transplantation, syngeneic transplantation, matched sibling donor transplantation, unrelated donor transplantation and haploidentical transplantation * The patients themselves or their authorized clients agree to participate in the clinical study and sign the informed consent Exclusion Criteria: * Those with evidence of active fungal infection within 3 weeks prior to enrollment * Allergic to azole drugs * Severe abnormal liver function * Rifampicin, isoniazid, phenytoin, carbamazepine, and long-acting barbiturates were used in combination during the study * Any predictably increased patient risk or other factors that might interfere with the outcome of a clinical trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary fungal infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
-
Shanxi Bethune Hospital
Taiyuan, China
-
The Second Hospital of Hebei Medical University
Shijia Zhuang, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China